Abstract Number: 2564 • 2019 ACR/ARP Annual Meeting
Adherence to Hydroxychloroquine Influences the Incidence of Organ Damage During Follow-up in Patients with Systemic Lupus Erythematosus
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone drug in patients with systemic lupus erythematosus (SLE), decreasing the risk of flares and comorbidities and improving survival. This…Abstract Number: 2565 • 2019 ACR/ARP Annual Meeting
Pharmacokinetics and Exposure-response of Intravenous Belimumab in Children with Systemic Lupus Erythematosus
Background/Purpose: Belimumab is approved in adults with active SLE and for childhood-onset SLE (cSLE). PLUTO, a Phase 2, placebo-controlled, double-blind trial (114055; NCT01649765), was the first…Abstract Number: 2566 • 2019 ACR/ARP Annual Meeting
Polypharmacy and Potentially Inappropriate Medication Use in Young versus Older Adults with SLE
Background/Purpose: Polypharmacy, typically defined as ≥ 5 medications (meds), is a strong risk factor for adverse clinical outcomes, including delirium, falls, hospitalization, and death, especially…Abstract Number: 2567 • 2019 ACR/ARP Annual Meeting
Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates
Background/Purpose: Hydroxychloroquine (HCQ) is the most well established therapy for SLE, as it provides several beneficial properties, such as favorable effects on lipid profile, reduced…Abstract Number: 2568 • 2019 ACR/ARP Annual Meeting
Iguratimod Is an Alternative Option for Refractory Lupus Nephritis: A Preliminary Observational Study
Background/Purpose: Despite significant advances in the management of patients with lupus nephritis (LN), a significant proportion of patients either do not respond to first-line immunosuppressive…Abstract Number: 2569 • 2019 ACR/ARP Annual Meeting
Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review
Background/Purpose: The purpose of this systematic review was to identify existing guidelines for antimalarial prescribing and monitoring in rheumatic diseases, specifically for hydroxychloroquine, and how…Abstract Number: 2570 • 2019 ACR/ARP Annual Meeting
Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis
Background/Purpose: Proliferative lupus nephritis (LN) is one of the most common and serious manifestations of SLE and is a major cause of morbidity. A search…Abstract Number: 2571 • 2019 ACR/ARP Annual Meeting
Early Improvement in SLEDAI-2K Responder Index-50 Predicts SRI-4 Response in a Randomized Placebo-Controlled Trial of Ustekinumab (UST) in Systemic Lupus Erythematosus
Background/Purpose: While traditional Systemic Lupus Erythematosus (SLE) Disease Activity Index 2000 (SLEDAI-2K) scoring assesses complete SLE response for individual disease manifestations, the SLEDAI-2K Responder Index-50…Abstract Number: 2572 • 2019 ACR/ARP Annual Meeting
Efficacy Analysis of Patients with Systemic Lupus Erythematosus Treated with Belimumab or Placebo Plus Standard Therapy in Phase 3 Trials by Baseline Levels of BLyS mRNA and Type 1 Interferon Inducible Gene Signature Status
Background/Purpose: Belimumab (BEL) is a B-lymphocyte stimulator (BLyS) inhibitor approved as an add-on to standard of care (SoC) for patients with autoantibody-positive SLE with active…Abstract Number: 2573 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: Comparison of Whole Blood and Serum Levels
Background/Purpose: Hydroxychloroquine (HCQ) levels can be measured in whole blood as well as in serum but both methods have never been compared. Cut offs for…Abstract Number: 2574 • 2019 ACR/ARP Annual Meeting
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of BIIB059, a Monoclonal Antibody Targeting BDCA2 Following Administration of Subcutaneous Single Doses in Japanese Healthy Volunters
Background/Purpose: Background: BDCA2 is a plasmacytoid dendritic cell (pDC)-specific receptor that, when ligated inhibits the production of inflammatory mediators and Type I Interferon (INF), a…Abstract Number: 2575 • 2019 ACR/ARP Annual Meeting
Electronic Monitoring of Medication Adherence in Young Adults with Childhood-Onset Systemic Lupus Erythematosus over 12 Weeks
Background/Purpose: Young adults with childhood-onset lupus (cSLE) are 20 times more likely to die compared to healthy age- and gender-matched counterparts. Their clinical course is…Abstract Number: 2576 • 2019 ACR/ARP Annual Meeting
Clinical Evidence Supporting Therapeutic Potential of Activating the Immune Checkpoint Receptor BTLA in SLE
Background/Purpose: Background/Purpose: Immune checkpoint inhibitors have demonstrated durable benefit in some cancer patients. However, checkpoint inhibitors are also associated with new onset autoimmune adverse events. …Abstract Number: 2577 • 2019 ACR/ARP Annual Meeting
SLE Disease Activity May Be Associated with Choroidal Thickness
Background/Purpose: SLE is an autoimmune disease with widespread organ involvement. High disease activity has previously been associated with higher risk of organ damage and mortality.…Abstract Number: 2578 • 2019 ACR/ARP Annual Meeting
Effect of Omega-3 Fatty Acids on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis
Background/Purpose: Omega-3 fatty acids may have anti-inflammatory properties. In animal models of systemic lupus erythematosus (SLE) Omega-3 fatty acids decrease autoantibody levels, reduce inflammatory markers…
ACR Meeting Abstracts